Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, will be presenting at the World Orphan Drug Congress USA Conference. The three-day event is scheduled for Aug. 25-27. Processa CEO and chair Dr. David Young will be the company representative doing the presentation. His presentation is titled “Balancing the Benefit-Risk of an Orphan Drug: Case Studies.” Young’s presentation is slated for Wednesday, Aug. 25, 2021, at 1:30 p.m. ET. PCSA is intent on developing drug products that improve the survival and quality of life for patients with high unmet medical need conditions. The company seeks to identify and develop drugs for patients who need better treatment options than presently exist for their medical condition.
To view the full presentation, visit https://ibn.fm/Ze9NL
To view the full press release, visit https://ibn.fm/Dfb1B
About Processa Pharmaceuticals Inc.
The mission of Processa is to develop drug products that improve the survival and/or quality of life for patients with high unmet medical need conditions. Processa is a development company, not a discovery company, that seeks to identify and develop drugs for patients who need better treatment options than presently exist for their medical condition. To increase the probability of development success, the company’s pipeline only includes drugs that have previously demonstrated some efficacy in the targeted population or a drug with similar pharmacological properties that has been shown to be effective in the population. Processa currently has three drugs in various stages of clinical development: PCS499 for ulcerative necrobiosis in phase 2B, PCS3117 for metastatic pancreatic cancer and non-small cell lung cancer in phase 2B, and PCS6422 for metastatic colorectal cancer and breast cancer in phase 1B. The PCS12852 IND for the treatment of gastroparesis will be submitted in 3Q 2021. Members of the Processa development team have been involved with more than 30 FDA drug approvals, including drug products targeted to orphan-disease conditions; more than 100 FDA meetings; and two FDA regulatory science contracts. For more information, visit the company’s website at www.ProcessaPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
